PHOENIX

Project PHOENIX: Molecular Signatures of Burn Pit Exposure

Ensayo de CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. en Burn Pit Exposure · Airborne Hazard Exposure · Veteran Health · Deployment-Related Toxic Exposure · Biomarkers · Immune Dysfunction · Respiratory Symptoms (del registro, en inglés).

Fase: no aplica
Estado: Aún sin reclutar
Participantes: 1.000
Fin del objetivo primario: may 2029

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en may 2026.

Qué mide

Differential gene expression (RNA-seq normalized counts) between burn pit-exposed and unexposed cohorts (del registro, en inglés) (inicio)

Cómo lo describe el promotor

En el documentoEn inglés, del registroProject PHOENIX is an observational clinical research study designed to characterize molecular, genomic, cellular, and functional features in blood specimens from former U.S. Service Members with prior burn pit exposure and from matched unexposed controls. Participants will complete screening, informed consent, health and exposure questionnaires, and a one-time blood collection. Blood-derived specimens may undergo genomic, epigenomic, transcriptomic, proteomic, metabolomic, immunophenotyping, and cellular functional analyses. Participants may also agree to optional future re-contact for health updates and possible repeat blood collection. The goal is to identify biologic signatures associated with prior deployment-related burn pit exposure and to support future biomarker discovery and translational research in veteran health.

Más ensayos de CELZ

Ensayo	Fase	Estado	Lectura de resultados
CELZ-201-DDT · ADAPT	Fase 1/2	En marcha, sin reclutar	ene 2027 (prevista)
CELZ-201 Administration · CREATE-1	Fase 1/2	Reclutando pacientes	ene 2027 (prevista)
CELZ-201-DDT · ADAPT	no aplica	Disponible por acceso ampliado	sin fecha

Todos los de CELZ, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07562243), actualizada en abr 2026.